|
Roche Diagnostics Awarded Immunoassay Contract by AmeriNet®
Indianapolis, IN. -- Today, Roche Diagnostics Corporation announced
that it has been awarded a new contract to provide immunoassay instruments,
reagents, and consumables to AmeriNet members. Covered under this
contract are Elecsys® assays for proBNP, troponin T, PSA, D-Dimer,
and the hepatitis portfolio, as well as therapeutic drug monitoring
and drugs-of-abuse assays. Effective June 1, 2003, the three-year
contract has a total value of close to $500 million.
This new contract continues a long-term relationship between AmeriNet
and Roche Diagnostics in the areas of clinical chemistry, hematology,
blood glucose monitoring, and hospital point-of-care testing. It
is the first new award for Roche Diagnostics under AmeriNet's new
strategy of competitively bidding major contract categories to bring
more value to their membership and to their trading partners.
"Roche Diagnostics offers AmeriNet members a broad portfolio
of platforms to meet our membership's diverse needs, from satellite
facilities to central core labs. Roche's ongoing commitment to new
product development leads the industry," said Bud Bowen, President
of AmeriNet.
"The new contract attests to the high level of satisfaction
of AmeriNet members with Roche Diagnostics," added Dick Aderman,
Senior Vice President and General Manager, Roche Centralized and
Molecular Diagnostics. "We are delighted to continue our long-time
collaboration with AmeriNet to help its members increase laboratory
efficiency and enhance patient care through timely, actionable clinical
information."
Under the contract, AmeriNet members will have access to Roche's
Elecsys platform, including the MODULAR® ANALYTICS E 170, Elecsys
2010 analyzer, and Elecsys 1010 analyzer, as well COBAS Integra®,
Roche/Hitachi, and MODULAR ANALYTICS chemistry modules. The test
menu covered by this contract comprises all immunoassays including
therapeutic drug monitoring (TDM) and drugs-of-abuse testing (DAT).
About AmeriNet
Founded in 1986, St. Louis-based AmeriNet, Inc. operates through
its three shareholder healthcare organizations: AmeriNet Central,
Intermountain Health Care, Inc., and Vector. Choice makes AmeriNet
unique in the healthcare GPO industry, and creates remarkable value
and cost savings for its members.
One of the nation's most successful group purchasing organizations,
AmeriNet is GPO of choice for a diverse industry including over
1,800 hospitals and over 16,000 non-acute members, creating value
and purchasing strength through an array of programs and services.
About Roche and the Roche Diagnostics Division
Headquartered in Basel, Switzerland, Roche is one of the world's
leading innovation-driven healthcare groups. Its core businesses
are pharmaceuticals and diagnostics. Roche is number one in the
global diagnostics market, the leading supplier of pharmaceuticals
for cancer, and a leader in virology and transplantation. As a supplier
of products and services for the prevention, diagnosis, and treatment
of disease, the Group contributes on a broad range of fronts to
improving people's health and quality of life. Roche employs approximately
62,000 people in 150 countries. The Group has alliances and research
and development agreements with numerous partners, including majority
ownership interests in Genentech and Chugai. Roche's Diagnostics
Division, the world leader in in-vitro diagnostics with a uniquely
broad product portfolio, supplies a wide array of innovative testing
products and services to researchers, physicians, patients, hospitals,
and laboratories worldwide. For further information, please visit
our websites www.roche.com
and www.roche-diagnostics.com.
ELECSYS, MODULAR, and COBAS INTEGRA are trademarks of a Member
of the Roche Group. AmeriNet is a trademark of AmeriNet, Inc.
|
